4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp
Sector(s):
Industry:
Full-time employees: 11,067
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Haruo Naito | CEO, Representative Corporate Officer & Director | N/A | N/A | 1947 |
Mr. Gary Hendler | Senior VP & President of EMEA Region | N/A | N/A | 1966 |
Ms. Yanhui Feng | Senior Vice President | N/A | N/A | 1972 |
Dr. Nadeem Sarwar Ph.D. | President | N/A | N/A | N/A |
Mitsuru Shomon | VP & CFO | N/A | N/A | N/A |
Makoto Hoketsu | VP & Chief Information Officer | N/A | N/A | N/A |
Ms. Sayoko Sasaki | Vice President of Corporate Communications & ESG | N/A | N/A | 1968 |
Mr. Teiji Kimura | Head of Academia Industry Alliance, DHBL Office | N/A | N/A | 1963 |
Mr. Tatsuyuki Yasuno | Senior VP & President of Americas Region | N/A | N/A | 1968 |
Mr. Shohei Kanazawa | VP & President of Asia and Latin America Region - API Solutions | N/A | N/A | 1965 |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Eisai Co., Ltd.’s ISS governance QualityScore as of 1 July 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 7; Compensation: 1.